Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) EBT Margin: 2009-2025

Historic EBT Margin for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to -9,199.79%.

  • Cytokinetics' EBT Margin rose 2313908.00% to -9,199.79% in Q3 2025 from the same period last year, while for Sep 2025 it was -705.98%, marking a year-over-year increase of 1670790.00%. This contributed to the annual value of -3,826.33% for FY2024, which is 313929.00% up from last year.
  • Cytokinetics' EBT Margin amounted to -9,199.79% in Q3 2025, which was down 5,002.94% from -180.28% recorded in Q2 2025.
  • Cytokinetics' 5-year EBT Margin high stood at -15.38% for Q2 2022, and its period low was -57,391.16% during Q2 2024.
  • In the last 3 years, Cytokinetics' EBT Margin had a median value of -9,856.30% in 2025 and averaged -16,903.89%.
  • Per our database at Business Quant, Cytokinetics' EBT Margin slumped by 4,250,143bps in 2024 and then soared by 5,721,088bps in 2025.
  • Quarterly analysis of 5 years shows Cytokinetics' EBT Margin stood at -47.25% in 2021, then crashed by 680,441bps to -6,851.66% in 2022, then crashed by 119,750bps to -8,049.16% in 2023, then soared by 706,264bps to -986.52% in 2024, then surged by 2,313,908bps to -9,199.79% in 2025.
  • Its EBT Margin was -9,199.79% in Q3 2025, compared to -180.28% in Q2 2025 and -9,856.30% in Q1 2025.